Elution Lifetime Versus Disease Latency: A Quantitative Argument on Why Antibacterial Dental Implant Coatings Have Not Translated
- Paper type
- Hypothesis and Theory
- Status
- Original Work · Working Paper
- Keywords:
- antibacterial coatings · drug-eluting implants · peri-implantitis · release kinetics · sample size · clinical translation
Contents
Abstract
Background. Laboratory and animal studies of antibacterial and drug-eluting dental implant coatings are abundant, yet reviews find little human outcome evidence and, to our reading of the retrieved abstracts, no coating on the implant body that has been shown to reduce a clinical disease endpoint [1, 2]. Orthopaedic devices with antibiotic or silver coatings exist, but the evidence is mostly case series [3].
Hypothesis. A thin coating on a small implant carries a finite reservoir that, under plausible release kinetics and sulcular fluid turnover, keeps the local drug concentration above an inhibitory threshold for days to weeks. Peri-implantitis becomes manifest on a scale of years [4, 5]. The only outcome an eluting coating could plausibly change is early infection or early failure, which is rare in dentistry, so adequately powered trials need thousands of implants. Non-eluting surfaces face distinct problems (conditioning films, wear) and are treated separately.
Proposed approach. We derive a reservoir bound, compare first-order and Higuchi-type release with a flushed-compartment concentration model, and compute sample sizes for an early-failure trial. All coating, geometry and fluid parameters are assumptions, and the calculations are illustrative, not empirical. We list falsifiable predictions and a design for discriminating the hypothesis from commercial, regulatory and toxicity explanations.
Expected contribution. A quantitative, falsifiable formulation of the translation gap that identifies which coating architectures could escape it: renewable or replaceable surfaces, therapeutic rather than preventive use, enriched high-risk populations, and non-depleting mechanisms.
Conclusions. Mass balance alone does not forbid multi-year delivery in a favorable corner of parameter space; kinetics, biofilm-tolerant concentrations, inflamed-site fluid flux and trial power jointly make an effect on late disease implausible for a once-loaded implant-body coating. The argument is conditional on assumed parameters that should be replaced by measurements.
1. Introduction
Peri-implantitis is common. A recent AO/AAP meta-analysis of 102 studies reported patient-level prevalence of about one in five and weighted mean incidence of similar size within 20 years of function [5]. A biofilm-centered rationale therefore motivates the search for surfaces that resist or kill bacteria, and the literature on such surfaces is large. A systematic review restricted to studies with at least 48 hours of bacterial growth analysis still found 40 studies, with antibacterial peptides, synthetic antimicrobial molecules and silver nanoparticles as the main categories, and it concluded that more in vitro and preclinical work was needed to judge real potential [1].
The clinical record is thin. Translation reviews of nano-engineered titanium describe promising proof-of-concept results in vitro, ex vivo and in short in vivo studies, while flagging mechanical stability, corrosion, sterilization, aging and nanotoxicity as unresolved [2]. In orthopaedics, where coated devices have reached patients, a risk-benefit review identified only nine clinical studies with 435 patients across four technologies, seven of them case series, and noted that randomized trials are difficult because infection prevention needs large samples [3].
This manuscript asks a narrower question than “why has translation failed?” Commercial, regulatory and standardization explanations are plausible and are treated as competing hypotheses (Section 5). The question here is whether a physical and statistical reason suffices on its own. The reasoning has three steps. First, a coating of micrometer thickness on an implant of a few hundred square millimeters contains at most about a milligram of active agent, as bounded in Section 3. Second, release from such a coating is expected to be front-loaded, so the time above an inhibitory concentration in a fluid that is continuously replaced is measured in days to weeks under the assumptions we state. Third, peri-implantitis onset is modeled as occurring mainly within about three years of function in one cohort analysis [4], and incidence keeps rising for a decade or more [5]. An eluting coating can therefore address, at most, a perioperative infection that already occurs infrequently, and demonstrating a benefit requires very large trials.
The contribution is a quantitative formulation, not a new observation. Orthopaedic authors have stated the large-sample problem qualitatively [3], and trial sequential analyses exist for antibiotic prophylaxis in implant surgery [6]. We have not found, in the sources searched, a paper that combines a reservoir bound, release kinetics against disease latency and a dental sample-size table (see the Novelty assessment). The manuscript is a theory paper. No experiments, patient data or simulations of patient outcomes were produced; the only computations are closed-form calculations and one Monte Carlo power check, labeled as illustrative.
2. Background and critical appraisal of the evidence
The origin of the concept: release-controlled delivery and its mathematics
Diffusion-controlled release from a drug-loaded matrix has a long theoretical history. The square-root-of-time law for release from a matrix with suspended drug is usually attributed to Higuchi [7]. For a thin planar coating releasing through one face, the short-time solution of Fick’s second law gives the same square-root dependence on time, and release approaches exhaustion exponentially once the front reaches the substrate. The dental coating literature adopted this vocabulary of burst, sustained and triggered release from pharmaceutics. What the pharmaceutical frame does not supply is a clinical clock: for an orally dosed drug the dosing interval matches the pharmacology, whereas an implant is placed once, for decades.
Dental antibacterial surfaces: breadth without outcomes
Reviews of titanium surface modification describe polymicrobial challenges and many modification routes [8, 9], and a narrative review of silver nanoparticle coatings pairs antibacterial effects with cytotoxicity concerns [10]. A systematic review and meta-analysis of titania nanotube surfaces and systematic reviews of antimicrobial abutment coatings similarly address laboratory and short-term endpoints [11, 12, 13]. The human studies we identified at abstract level concern abutment-level surfaces. A split-mouth randomized clinical trial of a nano-silver coating on healing abutments reported suppressed plaque adhesion [14], and a clinical study of an internal antibacterial coating was designed around short-term microbiological readouts [15]. These are plausible biological signals. None is an incidence endpoint, and neither addresses the implant body.
Our searches of ClinicalTrials.gov for antibacterial coated dental implants returned no implant-body drug-eluting trial; the results were orthodontic miniscrew, orthodontic band and unrelated registrations. This is an absence at the level of one search and should be re-checked with full registry vocabulary.
The orthopaedic comparison: what reached the clinic and why
Orthopaedic devices show both the possibility and the limits. A multicenter randomized trial of an antibiotic-loaded, fast-resorbable hydrogel coating in 380 hip or knee arthroplasty patients, with mean follow-up of 14.5 months, reported 11 early surgical site infections in the control group and one in the coated group (6% versus 0.6%) [16]. The hydrogel is designed to resorb quickly, and the endpoint was early infection. That match between release window and endpoint is the central observation of this paper. A later systematic review of the same coating in hip surgery judged the evidence insufficient either to encourage or discourage use [17], and a published randomized trial protocol compares single-stage surgery with hydrogel-coated implants against two-stage surgery for chronic infection, a therapeutic rather than preventive use [18].
For silver, a review of megaprostheses and a meta-analysis of 11 studies with 1,419 patients reported lower infection rates with silver coating (9.2% versus 13.4%) but the data were drawn from comparative and observational studies of megaprosthesis settings, where baseline risk is high [19, 20]. For gentamicin-coated intramedullary nails, a systematic review found 22 publications on 506 infected non-unions, mostly retrospective case series, with a reported infection eradication rate of 90% and an explicit call for randomized trials [21]. In these settings, baseline infection risk is high and the coating acts at or shortly after surgery.
Two points follow. Coatings reached the clinic where baseline event rates were high enough and the endpoint early enough for modest trials or accepted case series. And even there, evidence quality is low [3, 21]. The dental situation lacks both features.
Why the reporting itself resists synthesis
A critical review of antibacterial surfaces for load-bearing orthopaedic implants argued that efficacy verdicts depend on the assay, and that none of 13 open-access studies tested against its checklist related antibacterial dose to a stated cytotoxicity threshold [22]. A design-oriented review likewise lists durability and translational barriers [23]. These observations support the competing hypothesis that standardization, not physics, limits translation. They do not address the arithmetic of release against latency, and the two explanations can be true together.
The dental epidemiology that sets the clock and the base rate
Disease latency. In a 9-year follow-up of 596 randomly selected implant carriers, 62 patients had moderate or severe peri-implantitis, and a growth model of marginal bone loss in the 105 affected implants indicated non-linear, accelerating loss with onset for most cases within three years of function: 52% and 66% of affected implants had estimated bone loss above 0.5 mm at years 2 and 3 [4]. The sample is restricted to patients who developed disease, and onset is a model estimate, so the figure is a coarse clock. A 25-year prospective cohort reported peri-implantitis at the implant level rising from 3.5% at 10 years to 9.1% at 25 years [24], and the AO/AAP synthesis gave prevalence and incidence of the order of one in five patients [5]. Disease keeps accumulating years after any plausible elution window.
Early base rate. Early failure before loading is uncommon. A retrospective single-source series reported 53 early failures among 1,323 implants in 738 patients, about 4.0% [25]. Risk factors there included smoking, posterior maxilla, bone type IV and previously augmented sites, which suggests that enrichment could raise event rates. Long-term implant failure was 1.2% at 10 years in a prospective cohort [24]. Systematic reviews of antibiotic prophylaxis, which is a systemic comparator for any local release, are discordant in emphasis. One meta-analysis of 8 randomized trials with 2,869 implants found fewer failures with prophylaxis but warned that conclusions were not definitive [26]. Another, with 7 trials, 1,859 patients and 3,014 implants, found no significant difference (risk ratio 0.66, 95% confidence interval 0.30 to 1.47), with a risk difference of -0.007 and a number needed to treat of 143 [27]. A further meta-analysis of 12 trials judged routine prophylaxis not sufficiently effective to justify its use [28], and an earlier Cochrane review addressed the same question [29]. The wide interval in the most recent synthesis is itself a demonstration of the power problem.
Coating-delivered drugs that do not target bacteria: a cautionary parallel
Bisphosphonate-eluting coatings show how a promising early-window effect can fail to replicate. A pilot, a paired double-blind randomized trial in 16 patients and a 5-year radiographic follow-up reported greater fixation and less marginal bone loss with the coated implant [30, 31, 32]. In the paired trial, resonance frequency rose 6.9 ISQ units more with the coated implants at 6 months [31]. A multicenter parallel-group trial of a zoledronate coating randomized 62 patients and analyzed 49, and found no significant difference in stability or marginal bone level at one year [33]. Chemistry, design and endpoints differ between these studies, so the contrast does not demonstrate that the effect is absent. It does show that single-center paired designs with small samples can mislead, and that drug-releasing coatings need adequately powered parallel trials. The relevance here is methodological: an early-window effect on bone fixation is mechanistically credible for a coating whose release matches the healing period, which is the same logic as the argument for early infection.
| Source | Design and size | Finding relevant here | Main bias or limitation | Level |
|---|---|---|---|---|
| Teulé-Trull 2025 [1] | Systematic review, 40 in vitro and preclinical studies | Peptides most studied; more preclinical work needed | Abstract-level appraisal; laboratory studies | C |
| Alt 2017 [3] | Clinical review, 9 studies, 435 patients | Mostly case series; large RCTs challenging | Low evidence level | C |
| Romanò 2016 [16] | Multicenter RCT, n = 380, mean 14.5 months | Early infection 6% versus 0.6% with fast-resorbing coating | Few events (12); abstract only | B |
| Derks 2016 [4] | Cohort, 596 individuals, 62 cases, 9 years | Onset mostly within 3 years; non-linear progression | Modeled onset; diseased subsample | B |
| Galarraga-Vinueza 2025 [5] | Meta-analysis, 102 studies | Prevalence about 21%; incidence 22% within 20 years | Heterogeneous definitions | B |
| Momand 2024 [27] | Meta-analysis of 7 RCTs, 3,014 implants | RD -0.007, NNT 143, wide CI | Imprecision | B |
| Yari 2024 [25] | Retrospective cohort, 1,323 implants | Early failure 53 events (about 4.0%) | Single source, confounding | C |
| Mokhtari 2024 [33] | Parallel RCT, 62 randomized, 49 analyzed | No stability or bone difference at 1 year | Attrition, short follow-up | B |
| Odatsu 2020 [14] | Split-mouth RCT on abutments, in vitro work | Plaque adhesion suppressed | Short-term surrogate | C |
3. Hypothesis and theoretical framework
Formal statement
H1 (timescale and mass-balance mismatch). Let t_(eff) be the cumulative time during which the drug concentration in the peri-implant fluid compartment exceeds an effective threshold C^*, and let T_L be the latency of the clinical disease of interest. For an implant-body coating that is applied once at manufacture, t_(eff)/T_L is well below 1 for realistic loading, release kinetics and fluid turnover, so the coating cannot reduce the incidence of a disease whose causal period lies beyond t_(eff).
H2 (power). The only clinical outcome that lies inside t_(eff) is early infection or early failure. Its baseline risk in general dental practice is a few percent or less, so a superiority trial needs on the order of 10^3 implants per arm for a 50% relative reduction and more for smaller effects.
H3 (scope). Non-eluting surfaces (contact-killing, anti-adhesive) are not bound by H1 because they have no reservoir, but they face different failure modes, namely conditioning by salivary and serum proteins, wear during insertion and function, and coating delamination.
H1 is a conditional statement about a parameter region, not a universal law. Section 3.5 states which parameter corner would falsify it.
Assumptions
All values in this section are assumptions chosen to be physically plausible and to favor the coating where doubt exists. They are not measurements from any source, and the computations in this section are labeled Illustrative computation under stated assumptions — not empirical data. The scripts (calc29.py, calc29b.py) and their output files are in the paper folder.
- A1 Geometry. A cylindrical implant of diameter D=4.1 mm and length L=10 mm. The lateral area πDL is multiplied by a thread and roughness factor of 2.0, giving A=2.58 cm2. This is a round-number assumption, not a manufacturer’s specification.
- A2 Only a fraction f_c=0.30 of this area (0.77 cm2) can face the peri-implant sulcus or pocket after marginal bone loss. This is generous for early disease.
- A3 Coating density ρ=1.2 g/cm3, thickness h of 1, 10 or 50 µm, and a drug mass fraction ϕ of 0.1 or 0.3. The 50 µm case on a threaded surface is unlikely to be mechanically feasible and serves as an upper bound.
- A4 All drug released from the coronal fraction enters the sulcular fluid (a favorable simplification). Bone-side release is ignored for late disease.
- A5 The compartment is well mixed and continuously replaced at flow Q. Two values are used: Q=0.144 mL/day (0.1 µL/min) for a healthy site and Q=1.44 mL/day (1 µL/min) for an inflamed site. A pilot split-mouth study found that healthy peri-implant and periodontal sites produced comparable fluid volumes, lower than in diseased sites [34]; the abstract gives no usable flow rates, so the magnitudes above are assumptions.
- A6 Threshold C^* is either 2 µg/mL, an assumed planktonic inhibitory level for a gentamicin-like agent, or 100 times that value (200 µg/mL) as an assumed biofilm-tolerant level. Both are placeholders.
- A7 Latency T_L=730 days (two years), chosen conservatively from the modeled onset within about three years [4].
Reservoir bound
The maximum drug mass available is
M_(max)=A h ρ ϕ (1)
with A in cm2, h in cm, ρ in g/cm3 and ϕ dimensionless, so that M_(max) is in grams. Under A1 to A3 the whole-body and coronal reservoirs are as follows (output of calc29.py).
Illustrative computation under stated assumptions — not empirical data. For A=2.58 cm2 and ρ=1.2 g/cm3 (output of calc29.py), the whole-body bound is 0.031 and 0.093 mg at h=1 µm (ϕ=0.1 and 0.3), 0.309 and 0.927 mg at 10 µm, and 1.546 and 4.637 mg at 50 µm. For the coronal fraction (f_c=0.30) the corresponding values are 0.009 and 0.028 mg, 0.093 and 0.278 mg, and 0.464 and 1.391 mg.
The relevant point is the ratio between reservoir and the drug mass needed to hold a concentration in a flushed compartment, which is formalized next.
Release kinetics and the time above threshold
First-order release. With release rate constant k=ln2/t_(1/2),
M(t)=M_0(1−e^(−kt)), R(t)=M_0 k e^(−kt) (2)
where M_0 is the reservoir mass (mg), t_(1/2) the release half-time (days) and R the release rate (mg/day).
Higuchi-type diffusion-limited release. For a planar coating of thickness h releasing through one face into a perfect sink, the early-time fraction released is
f(t)=(M(t))/M_0=2√((D t)/(πh^2)), f≲0.6 (3)
with D the effective diffusivity in the coating (m2/s). Solving for f=0.6 gives t_(0.6)=π(0.6)^2h^2/(4D). This is the square-root-of-time behavior associated with Higuchi’s analysis [7] but, strictly, it is the monolithic-slab form and not Higuchi’s suspension model; we use it as a simple diffusion-limited surrogate. Output of calc29.py: for h=10 µm, t_(0.6) is 0.327, 3.27 and 32.7 days for D=10^(−15), 10^(−16) and 10^(−17) m2/s; for h=1 µm it is 0.0033, 0.033 and 0.33 days; for h=50 µm it is 8.2, 82 and 818 days. Time scales as h^2/D, so a 50 µm coating with very low diffusivity can last years, but only if a drug can be loaded at that thickness and then diffuse out at a rate that still reaches C^*. Under first-order release with t_(1/2) of 0.5, 1, 3, 7 and 14 days, the fraction released by day 28 is 1.000, 1.000, 0.998, 0.938 and 0.750 respectively, and by day 730 it is 1.000 in all cases.
Concentration in a flushed compartment. If released drug is diluted in fluid replaced at flow Q (mL/day), the quasi-steady concentration is
C(t)=(R(t))/Q (4)
For first-order release, C(t) exceeds C^* only while M_0ke^(−kt)>QC^*, so
t_(eff)=1/kln(M_0k/(QC^*)) if M_0k>QC^*, otherwise 0 (5)
Two consequences follow. First, if release is front-loaded, the factor M_0k must be large relative to QC^* at the start, and the logarithm then makes t_(eff) grow only slowly with reservoir size: doubling M_0 adds ln2/k=t_(1/2) days. Second, a mass-balance ceiling applies even for perfectly constant (zero-order) release:
t_(ceiling)=M_0/(Q C^*) (6)
| Flow Q | Threshold C* (µg/mL) | t½ = 1 d | t½ = 7 d | t½ = 14 d | Zero-order ceiling |
|---|---|---|---|---|---|
| Healthy, 0.1 µL/min | 2 | 9.4 | 46.1 | 78.1 | 966 |
| Healthy, 0.1 µL/min | 200 | 2.7 | 0 | 0 | 9.7 |
| Inflamed, 1 µL/min | 2 | 6.1 | 22.8 | 31.6 | 96.6 |
| Inflamed, 1 µL/min | 200 | 0 | 0 | 0 | 1.0 |
Read honestly, the table does not show that mass balance forbids two-year delivery. In the most favorable corner (healthy flow, planktonic threshold, a 10 µm coating at 30% loading, strictly zero-order release), the ceiling is 966 days. That corner requires a release profile that diffusion-controlled coatings do not normally have. Under first-order release with a 14-day half-time, t_(eff) is 78.1 days, which is 10.7% of the 730-day latency, and the other rows are lower (6.31% for the 7-day half-time and 3.12% at inflamed flow). A reservoir able to hold the planktonic threshold for 730 days at healthy flow would need 0.21 mg (Equation 6), which is within the coronal reservoir of the 10 µm, 30% loading case (0.278 mg) but not the 10% loading case (0.093 mg); holding a biofilm-tolerant 200 µg/mL for 730 days at healthy flow would need 21.0 mg, and 2.10 mg at inflamed flow for the planktonic threshold. These are mass-balance statements with all drug assumed to enter the sulcus, so they are optimistic.
The refinement matters for the argument. The constraint is the product of three things: kinetics (front-loaded release), the biofilm-tolerant threshold (which is the relevant target for peri-implantitis, because established biofilm tolerates much higher concentrations than planktonic cells, a general principle we do not quantify here), and fluid flux in an inflamed site. Mass balance alone binds only for the biofilm-tolerant threshold and for thin coatings.
Falsifiable predictions
The following predictions are conditional on the assumptions above and are stated so that a measurement could contradict them.
- P1. For published dental implant-body coatings that report release, the median duration over which release exceeds the authors’ own stated inhibitory threshold is shorter than 10% of 730 days (73 days). Refuted if a systematic mapping finds that the majority of coatings sustain threshold-level release for at least 73 days under flow conditions.
- P2. In an in vitro flow model with a fluid replacement rate in the inflamed range (about 1 µL/min), time above a biofilm-tolerant threshold for a 10 µm coating is under 10 days for typical first-order profiles. Refuted by sustained concentrations above the threshold for longer than 30 days without replenishment.
- P3. In a randomized trial of an implant-body eluting coating with 3 to 5 years of follow-up, the effect on peri-implantitis incidence will be null, or indistinguishable from null with confidence limits excluding a relative risk below 0.7, whereas the effect on early failure will be detectable only in a sample of the size in Table 3. Refuted by a relative risk of peri-implantitis below 0.7 with confidence limits excluding 1.0 at 3 or more years.
- P4. Negative-control endpoint: within the same trial, the coating effect on late marginal bone loss beyond the release window is zero. Refuted by a persistent difference after release has ended and no residual drug detectable.
- P5. A therapeutic design (coating applied during surgical treatment of existing peri-implantitis, endpoint at 6 to 12 months) will show an effect size detectable in samples of the order of hundreds because baseline recurrence is high. This is a prediction about feasibility, not efficacy.
- P6. A renewable abutment-level antibacterial surface (replaceable at maintenance visits) will reduce peri-implant mucositis incidence at 1 to 3 years more than an implant-body coating of the same chemistry. Refuted if the implant-body coating performs equally.
- P7. Non-eluting contact-killing surfaces will show loss of in vitro activity after incubation in saliva or serum compared with pristine surfaces, and after simulated insertion wear. Refuted by retention of activity within 20% of pristine values.
What would not refute H1: a short-term reduction in plaque on an abutment, because plaque is a surrogate that sits inside the window [14, 15]. What would weaken it substantially: evidence that early colonization sets a trajectory for late disease (Section 5), which would make an early-window effect clinically important after all.
4. Proposed methodology
The hypothesis is tested by four linked work packages. None has been performed. Work package 1 is a literature-based meta-research mapping, work package 2 is a laboratory measurement, work package 3 is a clinical trial design, and work package 4 is a negative-control and discrimination design. The sample-size reasoning in work package 3 is the one quantitative element of the methodology that we can compute now.
Work package 1: mapping release duration against disease latency
Design. A systematic mapping of studies of dental implant coatings that report release, with the unit of analysis the coating, not the paper. Databases would be MEDLINE, Embase, Scopus and Web of Science plus trial registries; the present manuscript could reach only PubMed, Europe PMC and ClinicalTrials.gov, so the mapping remains to be done.
Extraction. Active agent, coating architecture, thickness, loading, release medium, whether flow was used, release duration to a stated threshold, the threshold itself, the longest in vitro antibacterial assay, the in vivo model and its duration, and any human endpoint. An existing 40-study review that required at least 48 hours of bacterial growth analysis suggests how short typical assay windows are [1], and a review of orthopaedic antibacterial surfaces proposed a ten-item minimum reporting checklist because efficacy readings depend on the assay [22]. We would adopt a similar checklist and add two items: whether release was measured under flow and whether the stated threshold relates to planktonic or biofilm tolerance.
Primary summary. For each coating, the ratio t_(eff)/T_L with T_L fixed a priori at 730 days, and its distribution across coatings (P1). Because many reports will not state a threshold, we would also report the proportion of coatings with no threshold at all, which is informative in itself.
Work package 2: laboratory measurement of the parameters assumed here
Every assumed parameter in Section 3 is replaceable by a measurement. We propose:
- Elution profiles of a small number of representative coatings (an antibiotic in a polymer, a silver-releasing layer, an antimicrobial peptide) in a flow cell at two flow rates matching assumed healthy and inflamed sulcular turnover, with concentration measured at defined intervals by a validated analytical method.
- Time above both a planktonic minimum inhibitory concentration and a biofilm-tolerance concentration measured on the same organism panel. The biofilm threshold must be measured and not inferred.
- Residual drug mass by exhaustive extraction at the end of the experiment, to close the mass balance.
- Retention of the coating after simulated insertion into bone-simulating material, since mechanical loss is a competing explanation for poor delivery.
- Sulcular fluid flow and volume at implant sites from a small clinical measurement study, because the published volumetric work we found is a ten-patient pilot without usable rates in its abstract [34].
Validity. Equations 2 to 5 are validated if measured t_(eff) falls within a factor of two of the model prediction after parameters are fitted on an independent coating batch. They are rejected as a description if release is dominated by mechanisms the model omits, such as erosion or triggered release.
Work package 3: sample size for an early-failure trial
Design. A parallel-group randomized trial of coated versus identical uncoated implants, patient as the randomization unit, with early failure before prosthetic loading as the primary endpoint. Early failure is a hard endpoint that lies inside any plausible elution window.
Formula. For two independent proportions p_1 (control) and p_2 (coated), two-sided type I error α and power 1−β, the sample size per arm in implants is
n=((z_(1−α/2)√(2pq)+z_(1−β)√(p_1q_1+p_2q_2))^2)/((p_1−p_2)^2) (7)
where p=(p_1+p_2)/2, q=1−p, q_i=1−p_i, z_(1−α/2)=1.960 and z_(1−β)=0.842. Multiple implants per patient inflate variance by the design effect 1+(m−1)ρ, with m implants per patient and ρ the intra-patient correlation. We assume m=1.79, which is the mean from a retrospective series of 1,323 implants in 738 patients [25], and ρ=0.2, an assumed value; the design effect is then 1.158. The pooled trials in one prophylaxis meta-analysis had 3,014 implants in 1,859 patients (1.62 implants per patient) [27], so m is plausibly lower in trials.
Baseline risks. The 4.0% value comes from the retrospective series just cited (53 of 1,323 implants) [25]. The 2% and 1% values are assumptions that represent lower-risk populations; they are not drawn from a source. Relative risk reductions of 0.5 and 0.7 are assumed effect sizes. For reference, the antibiotic prophylaxis meta-analysis gave a risk ratio of 0.66 with a wide interval and a risk difference of -0.007 [27].
| Control risk p1 | Relative risk (coated/control) | n per arm (implants, unadjusted) | n per arm (implants, clustered) | Patients per arm |
|---|---|---|---|---|
| 0.04 | 0.5 | 1,141 | 1,322 | 739 |
| 0.04 | 0.7 | 3,580 | 4,145 | 2,316 |
| 0.02 | 0.5 | 2,319 | 2,685 | 1,500 |
| 0.02 | 0.7 | 7,286 | 8,437 | 4,714 |
| 0.01 | 0.5 | 4,673 | 5,412 | 3,023 |
| 0.01 | 0.7 | 14,699 | 17,021 | 9,509 |
Three contrasts from the same script frame the result. With the orthopaedic early infection rates of 6% versus 0.6% [16], the required sample is 171 per arm, in line with the trial’s actual scale of 380 patients in total. With the dental risk difference of -0.007 from a baseline of 0.04 (0.040 versus 0.033), the required sample is 11,266 per arm. A late endpoint with an assumed 20% five-year incidence and relative risk 0.7 needs 615 per arm, which is feasible, but the coating is not expected to act on it (P3). The contrast makes the central point: in dentistry the endpoint that a coating could affect needs trial sizes far larger than the randomized trials we saw in the abstracts we read (for example 62 randomized patients [33]), while the endpoint that is feasible to power is the one the coating is not expected to reach. A single systematic review of antibiotic prophylaxis already illustrates the consequence, since seven trials with 1,859 patients could not exclude either no effect or a 70% relative reduction [27]. Trial sequential analysis has been applied to this question before [6].
Enrichment. Risk factors for early failure in the retrospective series, namely smoking, posterior maxilla, bone type IV and augmented sites [25], suggest that enrichment could raise p_1. Equation 7 shows that raising p_1 at a fixed relative reduction lowers the required sample, as the rows of Table 2 illustrate in reverse; we did not compute an enriched scenario. The cost is generalizability.
Statistical analysis plan. Mixed-effects or generalized estimating equation logistic regression with patient as cluster; the primary effect measure a risk ratio with 95% confidence interval; a pre-specified analysis adjusting for smoking, site, bone type and augmentation; intention to treat; an exact or Firth-type method for sparse events; and a pre-specified non-inferiority margin for a safety endpoint such as marginal bone loss at one year.
Bias control. Central randomization, concealed allocation, double blinding with visually identical implants, pre-registration, and independent adjudication of failure.
Ethics and feasibility. Placement of an implant bearing a drug is a drug-device combination that would need regulatory and ethics review in the relevant jurisdiction; we make no claim about approval. A trial of 1,300 to 17,000 implants per arm is feasible only as a multicenter or registry-embedded design, and the manufacturers would have to bear the cost, which is the commercial argument in the competing explanations.
Work package 4: discrimination and negative controls
The design in Section 5 contrasts the physical hypothesis with commercial, toxicity and trajectory explanations. The negative control (P4) is the late bone loss in the same trial beyond the end of measured release. A positive control is a coating for which the early window matches the endpoint, for example a fast-resorbing antibiotic layer evaluated on early surgical site infection, as in orthopaedics [16].
5. Competing explanations and how the design discriminates among them
C1. Commercial and regulatory barriers. The market is small relative to orthopaedic implants per product, trials are costly, and a drug-device combination faces a heavier pathway. This predicts that efficacious coatings exist but are not developed. It is discriminated from H1 by work package 1: if many coatings show t_(eff)/T_L near or above 1 and still have no trials, C1 is favored; if most are short-lived, H1 is favored. The two are not exclusive.
C2. Standardization and comparability. Efficacy verdicts depend on the assay, and doses are rarely related to cytotoxicity thresholds [22]. This predicts large variance between laboratories, not systematic shortness of release. It is discriminated by the release measurements of work package 2 on shared coatings across assays.
C3. Toxicity and dose limits. Silver coatings raise cytotoxicity concerns [10], and local gentamicin raises questions of resistance in orthopaedics, with contradictory data [3]. This predicts that mass is limited by safety rather than manufacturing, which would strengthen H1 through a lower M_0. It is discriminated by whether the toxicity ceiling lies below the mass needed in Equation 6.
C4. Mechanical delivery failure. Coatings may be abraded during insertion, and nano-engineered surfaces carry mechanical stability, sterilization and aging problems [2]. This predicts less drug on the implant than M_(max) and is discriminated by retention measurements in work package 2.
C5. Early colonization programs late disease. If colonization in the first weeks sets the microbial and inflammatory trajectory, then an early-window coating could change late incidence, and H1 would fail in its clinical implication though not in its physical statement. The abutment-level short-term plaque reductions [14, 15] are compatible with this idea but do not test it. It is discriminated by a trial with a late endpoint and a negative-control analysis of bone loss after release has ended (P4); a persistent late effect with early release would support C5.
C6. The endpoint is wrong because disease is host-driven. Risk indicators such as periodontitis, diabetes and smoking dominate in meta-analytic evidence [5]. If host factors dominate, even a perfect antibacterial would have a modest effect, and the issue is not the coating. It is discriminated by stratified analysis in a trial and does not change H1.
C7. Replication failure and small-trial optimism. The bisphosphonate coating program shows early positive paired trials followed by a null parallel trial [31, 32, 33]. This predicts that apparent efficacy in small dental coating trials is inflated, and it is discriminated by requiring parallel-group trials of the size in Table 3.
The mapping, the laboratory measurements and the trial together can attribute a null translation record to physics (short t_(eff)), to economics (long t_(eff) but no trials), or to biology (early window matters but the endpoint was not studied). Without work package 1 and 2, the data cannot separate them.
6. Clinical and engineering implications
These implications are conditional on H1 to H3 and on the assumed parameters. They are directions for evaluation, not recommendations for practice.
For developers of implant-body coatings. If the aim is to reduce late peri-implantitis, a once-loaded implant-body coating should be expected to fail unless it escapes the argument. The routes that could escape are listed below. If the aim is early infection or failure, the product claim should be early infection, the trial should be sized as in Table 3, and the population should be enriched for risk factors such as smoking, posterior maxilla, poor bone quality or augmented sites [25].
Coatings that could escape the argument.
- Renewable or replaceable surfaces. A transmucosal abutment or healing component can be exchanged at maintenance visits, resetting the reservoir. The reservoir is then refilled on a timescale comparable to T_L/n for n replacements. This is the logic behind the abutment-level studies [12, 13, 14, 15], although those studies measured surrogates.
- Therapeutic rather than preventive use. A coating applied during surgical treatment of existing disease has a short-latency endpoint (recurrence at 6 to 12 months) and a high baseline event rate, so Equation 7 gives a small n. The orthopaedic analogue is single-stage surgery with hydrogel-coated implants for chronic infection, now in a randomized protocol [18].
- Non-depleting mechanisms. Contact-killing, anti-adhesive or topographical surfaces have no reservoir, so H1 does not apply, but they must survive conditioning films and wear (H3, P7). Their evidence is also mostly in vitro [2, 11].
- Mass-independent delivery. Triggered release, external activation, or catalytic and enzymatic surfaces could decouple t_(eff) from M_0 in Equation 6. They would still need clinical-outcome evidence and face translational barriers [23].
- High-risk enrichment. Patients with uncontrolled risk factors have higher baseline event rates, reducing sample size, at the cost of a narrower indication.
- Host-directed coatings in the healing window. The bisphosphonate example shows that a coating aimed at early fixation matches its endpoint to its release window, although replication has been mixed [31, 33].
For clinicians. Marketing claims of antibacterial implant surfaces should be read against the question: antibacterial for how long, at what concentration, and against which endpoint? The absence of trials with a disease-incidence endpoint in our searches implies that the clinical benefit of such surfaces for peri-implantitis remains unproven, not that it is absent.
For regulators and standard-setters. A minimum reporting set for coatings, including release under flow, residual mass and the stated threshold, would allow the ratio t_(eff)/T_L to be audited, as a reporting checklist proposed for orthopaedic surfaces is intended to do [22]. Whether regulators would accept an early-failure surrogate is outside the scope of this paper.
7. Limitations
- Every physical parameter is assumed. Geometry, thread factor, coronal fraction, loading, diffusivity, release half-time, sulcular flow and thresholds are illustrative. Table 2 shows that the outcome swings by orders of magnitude within the assumed ranges. The reasoning is therefore a bound and a sensitivity analysis, not a forecast.
- The well-mixed, flushed compartment is a crude model. It ignores binding to proteins and tissue, diffusion into tissue, biofilm-matrix retention, tissue depots and the possibility that release into bone matters for early events. Tissue depots could extend effective exposure beyond the fluid-phase estimate.
- Mass balance does not by itself exclude long delivery. In the favorable corner the zero-order ceiling is 966 days. The argument relies on realistic kinetics and biofilm-tolerant thresholds, which are assumed and not measured here.
- The latency clock is soft. The estimate that most disease begins within three years comes from a model fitted to affected implants in one Swedish-type cohort design [4], and meta-analytic incidence is heterogeneous [5]. A different clock would change t_(eff)/T_L but not its order of magnitude unless T_L were measured in weeks.
- The early-failure baseline is from one retrospective series [25], and the lower risks used in the sample-size table are assumptions. True baselines vary with population and definition.
- Orthopaedic comparisons are indirect. Infection pathophysiology, device exposure and host factors differ, and the orthopaedic trials are themselves small or observational [3, 20, 21].
- Evidence appraisal was at abstract level. Full texts were not read, and Embase, Scopus and Web of Science were not accessible. Details such as follow-up, blinding and event counts may be misread.
- The argument does not address host-modulating or immunomodulatory coatings beyond the bisphosphonate example, and it does not evaluate any specific commercial product.
- Absence of trials is shown only by limited searches. A missed registry entry or a non-English publication would weaken the claim of no dental implant-body outcome evidence.
8. Conclusions
We propose that a mismatch between elution lifetime and disease latency, together with the low base rate of the endpoint a coating could reach, explains much of why antibacterial dental implant-body coatings have no clinical outcome record. Under illustrative assumptions, a thin coating holds well under a milligram in the coronal region, first-order release holds a planktonic threshold for weeks, and a biofilm-tolerant threshold in an inflamed site is not reached for more than a day or two. A trial powered on early failure at a 4% baseline and a 50% relative reduction needs about 1,141 implants per arm, and more than 11,000 per arm if the effect is the small risk difference seen with antibiotic prophylaxis. These are conditional results, and mass balance alone is not prohibitive in a favorable corner.
The hypothesis makes numbered predictions that measurements and trials could refute, and it identifies coatings that escape it: renewable or abutment-level surfaces, therapeutic use, high-risk enrichment and mass-independent mechanisms. Competing explanations (commercial, standardization, toxicity, mechanical loss and early-colonization programming) remain open and are not excluded.
Cite this paper
Jain S, Gupta A. Elution Lifetime Versus Disease Latency: A Quantitative Argument on Why Antibacterial Dental Implant Coatings Have Not Translated. Working paper. Center for Implant Dentistry; 2026. Available from: https://bayareaimplantdentistry.com/clinician-research-and-publications/antibacterial-coatings-elution-versus-latency
References
- Teulé-Trull M, Altuna P, Arregui M, Rodriguez-Ciurana X, Aparicio C. Antibacterial coatings for dental implants: A systematic review. Dent Mater. 2025;41(3):229-247. doi:10.1016/j.dental.2024.12.001 (opens in a new tab). PMID: 39658405 (opens in a new tab).
- Gulati K, Zhang Y, Di P, Liu Y, Ivanovski S. Research to Clinics: Clinical Translation Considerations for Anodized Nano-Engineered Titanium Implants. ACS Biomater Sci Eng. 2022;8(10):4077-4091. doi:10.1021/acsbiomaterials.1c00529 (opens in a new tab). PMID: 34313123 (opens in a new tab).
- Alt V. Antimicrobial coated implants in trauma and orthopaedics-A clinical review and risk-benefit analysis. Injury. 2017;48(3):599-607. doi:10.1016/j.injury.2016.12.011 (opens in a new tab). PMID: 28088378 (opens in a new tab).
- Derks J, Schaller D, Håkansson J, Wennström JL, Tomasi C, Berglundh T. Peri-implantitis - onset and pattern of progression. J Clin Periodontol. 2016;43(4):383-8. doi:10.1111/jcpe.12535 (opens in a new tab). PMID: 26900869 (opens in a new tab).
- Galarraga-Vinueza ME, Pagni S, Finkelman M, Schoenbaum T, Chambrone L. Prevalence, incidence, systemic, behavioral, and patient-related risk factors and indicators for peri-implant diseases: An AO/AAP systematic review and meta-analysis. J Periodontol. 2025;96(6):587-633. doi:10.1002/JPER.24-0154 (opens in a new tab). PMID: 40489307 (opens in a new tab).
- Canullo L, Troiano G, Sbricoli L, Guazzo R, Laino L, Caiazzo A, et al. The Use of Antibiotics in Implant Therapy: A Systematic Review and Meta-Analysis with Trial Sequential Analysis on Early Implant Failure. Int J Oral Maxillofac Implants. 2020;35(3):485-494. doi:10.11607/jomi.7995 (opens in a new tab). PMID: 32406644 (opens in a new tab).
- Higuchi T. Rate of Release of Medicaments from Ointment Bases Containing Drugs in Suspension. Journal of Pharmaceutical Sciences. 1961;50(10):874-875. doi:10.1002/jps.2600501018 (opens in a new tab).
- Barão VAR, Costa RC, Shibli JA, Bertolini M, Souza JGS. Emerging titanium surface modifications: The war against polymicrobial infections on dental implants. Braz Dent J. 2022;33(1):1-12. doi:10.1590/0103-6440202204860 (opens in a new tab). PMID: 35262547 (opens in a new tab).
- Chouirfa H, Bouloussa H, Migonney V, Falentin-Daudré C. Review of titanium surface modification techniques and coatings for antibacterial applications. Acta Biomater. 2019;83:37-54. doi:10.1016/j.actbio.2018.10.036 (opens in a new tab). PMID: 30541702 (opens in a new tab).
- Haugen HJ, Makhtari S, Ahmadi S, Hussain B. The Antibacterial and Cytotoxic Effects of Silver Nanoparticles Coated Titanium Implants: A Narrative Review. Materials (Basel). 2022;15(14). doi:10.3390/ma15145025 (opens in a new tab). PMID: 35888492 (opens in a new tab).
- Kunrath MF, Farina G, Sturmer LBS, Teixeira ER. TiO(2) nanotubes as an antibacterial nanotextured surface for dental implants: Systematic review and meta-analysis. Dent Mater. 2024;40(6):907-920. doi:10.1016/j.dental.2024.04.009 (opens in a new tab). PMID: 38714394 (opens in a new tab).
- Jennes ME, Naumann M, Peroz S, Beuer F, Schmidt F. Antibacterial Effects of Modified Implant Abutment Surfaces for the Prevention of Peri-Implantitis-A Systematic Review. Antibiotics (Basel). 2021;10(11). doi:10.3390/antibiotics10111350 (opens in a new tab). PMID: 34827288 (opens in a new tab).
- Campos MR, Reis ACD. Effect of Antimicrobial Agent Coating on Physicochemical and Biologic Properties of Implant Abutments: A Systematic Review. Int J Oral Maxillofac Implants. 2024;39(2):235-242. doi:10.11607/jomi.9992 (opens in a new tab). PMID: 38657216 (opens in a new tab).
- Odatsu T, Kuroshima S, Sato M, Takase K, Valanezhad A, Naito M, et al. Antibacterial Properties of Nano-Ag Coating on Healing Abutment: An In Vitro and Clinical Study. Antibiotics (Basel). 2020;9(6). doi:10.3390/antibiotics9060347 (opens in a new tab). PMID: 32575552 (opens in a new tab).
- Carinci F, Lauritano D, Bignozzi CA, Pazzi D, Candotto V, Santos de Oliveira P, et al. A New Strategy Against Peri-Implantitis: Antibacterial Internal Coating. Int J Mol Sci. 2019;20(16). doi:10.3390/ijms20163897 (opens in a new tab). PMID: 31405061 (opens in a new tab).
- Romanò CL, Malizos K, Capuano N, Mezzoprete R, D’Arienzo M, Van Der Straeten C, et al. Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty?. J Bone Jt Infect. 2016;1:34-41. doi:10.7150/jbji.15986 (opens in a new tab). PMID: 28529851 (opens in a new tab).
- Bove A, Braile A, Matino G, Del Regno N, Sirico S, Orabona N, et al. The Efficacy of Defensive Antibacterial Coating (DAC™) Periprosthetic Joint Infection Prevention in the Hip: A Systematic Review. J Clin Med. 2025;14(1). doi:10.3390/jcm14010270 (opens in a new tab). PMID: 39797352 (opens in a new tab).
- Boyer B, Cazorla C, Carricajo A, Labruyere C, Chapelle C, Presles E, et al. Single-stage surgery with antibiotic-loaded hydrogel-coated implants versus two-stage surgery for chronic periprosthetic hip joint infection in French tertiary referral hospitals: the SINBIOSE-H non-inferiority, randomised, controlled trial study protocol. BMJ Open. 2025;15(2):e085146. doi:10.1136/bmjopen-2024-085146 (opens in a new tab). PMID: 40000087 (opens in a new tab).
- Schmidt-Braekling T, Streitbuerger A, Gosheger G, Boettner F, Nottrott M, Ahrens H, et al. Silver-coated megaprostheses: review of the literature. Eur J Orthop Surg Traumatol. 2017;27(4):483-489. doi:10.1007/s00590-017-1933-9 (opens in a new tab). PMID: 28265758 (opens in a new tab).
- Bulut HI, Okay E, Kanay E, Batibay SG, Ozkan K. Comparative effectiveness of silver-coated implants in periprosthetic infection prevention: A systematic review and meta-analysis. J Orthop. 2025;61:133-139. doi:10.1016/j.jor.2024.10.009 (opens in a new tab). PMID: 39563860 (opens in a new tab).
- Walter N, Rupp M, Krückel J, Alt V. Individual and commercially available antimicrobial coatings for intramedullary nails for the treatment of infected long bone non-unions - a systematic review. Injury. 2022;53 Suppl 3:S74-S80. doi:10.1016/j.injury.2022.05.008 (opens in a new tab). PMID: 35613970 (opens in a new tab).
- Kwak IH, Choi H. The Standardization and Comparability Gap in Evaluating Antibacterial Surfaces for Load-Bearing Orthopedic Implants: A Critical Review. Bioengineering (Basel). 2026;13(9). doi:10.3390/bioengineering13090999 (opens in a new tab). PMID: 42791871 (opens in a new tab).
- Mao Z, Dong C, Jia Y, Li B, Zhijian W, Hu M. Antibacterial and Immunomodulatory Coatings for Orthopedic Metal Implants: Biological Rationale, Design Strategies, and Translational Challenges. Adv Healthc Mater. 2026;15(29):e00008. doi:10.1002/adhm.202600008 (opens in a new tab). PMID: 42402710 (opens in a new tab).
- Couso-Queiruga E, Roccuzzo A, Raabe C, Chappuis V, Buser D, Fonseca M, et al. Long-Term Incidence of Peri-Implant Conditions: 25-Year Results of The Bernese Prospective Cohort Study. Clin Implant Dent Relat Res. 2026;28(4):e70171. doi:10.1111/cid.70171 (opens in a new tab). PMID: 42423273 (opens in a new tab).
- Yari A, Fasih P, Alborzi S, Nikzad H, Romoozi E. Risk factors associated with early implant failure: A retrospective review. J Stomatol Oral Maxillofac Surg. 2024;125(4):101749. doi:10.1016/j.jormas.2023.101749 (opens in a new tab). PMID: 38145835 (opens in a new tab).
- Braun RS, Chambrone L, Khouly I. Prophylactic antibiotic regimens in dental implant failure: A systematic review and meta-analysis. J Am Dent Assoc. 2019;150(6):e61-e91. doi:10.1016/j.adaj.2018.10.015 (opens in a new tab). PMID: 31010572 (opens in a new tab).
- Momand P, Naimi-Akbar A, Hultin M, Lund B, Götrick B. Is routine antibiotic prophylaxis warranted in dental implant surgery to prevent early implant failure? - a systematic review. BMC Oral Health. 2024;24(1):842. doi:10.1186/s12903-024-04611-0 (opens in a new tab). PMID: 39054434 (opens in a new tab).
- Torof E, Morrissey H, Ball PA. Antibiotic Use in Dental Implant Procedures: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2023;59(4). doi:10.3390/medicina59040713 (opens in a new tab). PMID: 37109671 (opens in a new tab).
- Esposito M, Grusovin MG, Loli V, Coulthard P, Worthington HV. Does antibiotic prophylaxis at implant placement decrease early implant failures? A Cochrane systematic review. Eur J Oral Implantol. 2010;3(2):101-10. PMID: 20623035 (opens in a new tab).
- Abtahi J, Tengvall P, Aspenberg P. Bisphosphonate coating might improve fixation of dental implants in the maxilla: a pilot study. Int J Oral Maxillofac Surg. 2010;39(7):673-7. doi:10.1016/j.ijom.2010.04.002 (opens in a new tab). PMID: 20452185 (opens in a new tab).
- Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50(5):1148-51. doi:10.1016/j.bone.2012.02.001 (opens in a new tab). PMID: 22348981 (opens in a new tab).
- Abtahi J, Henefalk G, Aspenberg P. Randomised trial of bisphosphonate-coated dental implants: Radiographic follow-up after five years of loading. Int J Oral Maxillofac Surg. 2016;45(12):1564-1569. doi:10.1016/j.ijom.2016.09.001 (opens in a new tab). PMID: 27688166 (opens in a new tab).
- Mokhtari RA, Olsson M, Östman PO, Dahlin C. A randomized, multicenter, double-blinded parallel study to evaluate the safety and performance of zoledronate-coated versus uncoated dental implants in partially edentulous patients. Clin Implant Dent Relat Res. 2024;26(1):78-87. doi:10.1111/cid.13288 (opens in a new tab). PMID: 37849436 (opens in a new tab).
- Bevilacqua L, Biasi MD, Lorenzon MG, Frattini C, Angerame D. Volumetric Analysis of Gingival Crevicular Fluid and Peri-Implant Sulcus Fluid in Healthy and Diseased Sites: A Cross-Sectional Split-Mouth Pilot Study. Open Dent J. 2016;10:131-8. doi:10.2174/1874210601610010131 (opens in a new tab). PMID: 27335614 (opens in a new tab).

